Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer
- 1 July 2015
- journal article
- research article
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 10 (7) , 1099-1106
Abstract
No abstract availableKeywords
This publication has 44 references indexed in Scilit:
- Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' dataThe Lancet Oncology, 2013
- Tumor response and progression‐free survival as potential surrogate endpoints for overall survival in extensive stage small‐cell lung cancerCancer, 2010
- Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?Annals of Oncology, 2010
- Phase III Trial of Irinotecan/Cisplatin Compared With Etoposide/Cisplatin in Extensive-Stage Small-Cell Lung Cancer: Clinical and Pharmacogenomic Results From SWOG S0124Journal of Clinical Oncology, 2009
- Extensive-stage small-cell lung cancer—moving beyond response rate?Annals of Oncology, 2009
- Recommendations for the assessment of progression in randomised cancer treatment trialsEuropean Journal of Cancer, 2009
- Relationship between effects on time-to-disease progression and overall survival in studies of metastatic breast cancerBritish Journal of Cancer, 2008
- Randomized Phase II Study of Carboplatin and Etoposide With or Without thebcl-2Antisense Oligonucleotide Oblimersen for Extensive-Stage Small-Cell Lung Cancer: CALGB 30103Journal of Clinical Oncology, 2008
- Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702British Journal of Cancer, 2007
- Randomized Phase III Intergroup Trial of Etoposide and Cisplatin With or Without Paclitaxel and Granulocyte Colony-Stimulating Factor in Patients With Extensive-Stage Small-Cell Lung Cancer: Cancer and Leukemia Group B Trial 9732Journal of Clinical Oncology, 2005